Cargando…
Taxifolin and Lucidin as Potential E6 Protein Inhibitors: p53 Function Re-Establishment and Apoptosis Induction in Cervical Cancer Cells
SIMPLE SUMMARY: Human papillomavirus (HPV)-related cancers continue to be a major medical concern, and there exists an urgent need to improve the current therapeutic approaches by combining strategies or proposing new compounds to offer more specific and less invasive treatments. The aim of this wor...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221127/ https://www.ncbi.nlm.nih.gov/pubmed/35740499 http://dx.doi.org/10.3390/cancers14122834 |
_version_ | 1784732544594345984 |
---|---|
author | Gomes, Diana Yaduvanshi, Shivani Silvestre, Samuel Duarte, Ana Paula Santos, Adriana O. Soares, Christiane P. Kumar, Veerendra Passarinha, Luís Sousa, Ângela |
author_facet | Gomes, Diana Yaduvanshi, Shivani Silvestre, Samuel Duarte, Ana Paula Santos, Adriana O. Soares, Christiane P. Kumar, Veerendra Passarinha, Luís Sousa, Ângela |
author_sort | Gomes, Diana |
collection | PubMed |
description | SIMPLE SUMMARY: Human papillomavirus (HPV)-related cancers continue to be a major medical concern, and there exists an urgent need to improve the current therapeutic approaches by combining strategies or proposing new compounds to offer more specific and less invasive treatments. The aim of this work was to discover potential inhibitors of the E6/E6AP/p53 complex formation. We started this work with an initial in silico approach including molecular docking and molecular dynamics simulations, and these tools allowed us to select potential inhibitors, using E6 protein as a target. In addition, we found that lucidin and taxifolin were able to selectively decrease the viability of HPV-positive cells to re-establish p53 protein levels and to induce apoptosis. These findings represent a promising starting point for the development of anti-HPV drugs. ABSTRACT: Cervical cancer is the fourth leading cause of death in women worldwide, with 99% of cases associated with a human papillomavirus (HPV) infection. Given that HPV prophylactic vaccines do not exert a therapeutic effect in individuals previously infected, have low coverage of all HPV types, and have poor accessibility in developing countries, it is unlikely that HPV-associated cancers will be eradicated in the coming years. Therefore, there is an emerging need for the development of anti-HPV drugs. Considering HPV E6’s oncogenic role, this protein has been proposed as a relevant target for cancer treatment. In the present work, we employed in silico tools to discover potential E6 inhibitors, as well as biochemical and cellular assays to understand the action of selected compounds in HPV-positive cells (Caski and HeLa) vs. HPV-negative (C33A) and non-carcinogenic (NHEK) cell lines. In fact, by molecular docking and molecular dynamics simulations, we found three phenolic compounds able to dock in the E6AP binding pocket of the E6 protein. In particular, lucidin and taxifolin were able to inhibit E6-mediated p53 degradation, selectively reduce the viability, and induce apoptosis in HPV-positive cells. Altogether, our data can be relevant for discovering promising leads for the development of specific anti-HPV drugs. |
format | Online Article Text |
id | pubmed-9221127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92211272022-06-24 Taxifolin and Lucidin as Potential E6 Protein Inhibitors: p53 Function Re-Establishment and Apoptosis Induction in Cervical Cancer Cells Gomes, Diana Yaduvanshi, Shivani Silvestre, Samuel Duarte, Ana Paula Santos, Adriana O. Soares, Christiane P. Kumar, Veerendra Passarinha, Luís Sousa, Ângela Cancers (Basel) Article SIMPLE SUMMARY: Human papillomavirus (HPV)-related cancers continue to be a major medical concern, and there exists an urgent need to improve the current therapeutic approaches by combining strategies or proposing new compounds to offer more specific and less invasive treatments. The aim of this work was to discover potential inhibitors of the E6/E6AP/p53 complex formation. We started this work with an initial in silico approach including molecular docking and molecular dynamics simulations, and these tools allowed us to select potential inhibitors, using E6 protein as a target. In addition, we found that lucidin and taxifolin were able to selectively decrease the viability of HPV-positive cells to re-establish p53 protein levels and to induce apoptosis. These findings represent a promising starting point for the development of anti-HPV drugs. ABSTRACT: Cervical cancer is the fourth leading cause of death in women worldwide, with 99% of cases associated with a human papillomavirus (HPV) infection. Given that HPV prophylactic vaccines do not exert a therapeutic effect in individuals previously infected, have low coverage of all HPV types, and have poor accessibility in developing countries, it is unlikely that HPV-associated cancers will be eradicated in the coming years. Therefore, there is an emerging need for the development of anti-HPV drugs. Considering HPV E6’s oncogenic role, this protein has been proposed as a relevant target for cancer treatment. In the present work, we employed in silico tools to discover potential E6 inhibitors, as well as biochemical and cellular assays to understand the action of selected compounds in HPV-positive cells (Caski and HeLa) vs. HPV-negative (C33A) and non-carcinogenic (NHEK) cell lines. In fact, by molecular docking and molecular dynamics simulations, we found three phenolic compounds able to dock in the E6AP binding pocket of the E6 protein. In particular, lucidin and taxifolin were able to inhibit E6-mediated p53 degradation, selectively reduce the viability, and induce apoptosis in HPV-positive cells. Altogether, our data can be relevant for discovering promising leads for the development of specific anti-HPV drugs. MDPI 2022-06-08 /pmc/articles/PMC9221127/ /pubmed/35740499 http://dx.doi.org/10.3390/cancers14122834 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gomes, Diana Yaduvanshi, Shivani Silvestre, Samuel Duarte, Ana Paula Santos, Adriana O. Soares, Christiane P. Kumar, Veerendra Passarinha, Luís Sousa, Ângela Taxifolin and Lucidin as Potential E6 Protein Inhibitors: p53 Function Re-Establishment and Apoptosis Induction in Cervical Cancer Cells |
title | Taxifolin and Lucidin as Potential E6 Protein Inhibitors: p53 Function Re-Establishment and Apoptosis Induction in Cervical Cancer Cells |
title_full | Taxifolin and Lucidin as Potential E6 Protein Inhibitors: p53 Function Re-Establishment and Apoptosis Induction in Cervical Cancer Cells |
title_fullStr | Taxifolin and Lucidin as Potential E6 Protein Inhibitors: p53 Function Re-Establishment and Apoptosis Induction in Cervical Cancer Cells |
title_full_unstemmed | Taxifolin and Lucidin as Potential E6 Protein Inhibitors: p53 Function Re-Establishment and Apoptosis Induction in Cervical Cancer Cells |
title_short | Taxifolin and Lucidin as Potential E6 Protein Inhibitors: p53 Function Re-Establishment and Apoptosis Induction in Cervical Cancer Cells |
title_sort | taxifolin and lucidin as potential e6 protein inhibitors: p53 function re-establishment and apoptosis induction in cervical cancer cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221127/ https://www.ncbi.nlm.nih.gov/pubmed/35740499 http://dx.doi.org/10.3390/cancers14122834 |
work_keys_str_mv | AT gomesdiana taxifolinandlucidinaspotentiale6proteininhibitorsp53functionreestablishmentandapoptosisinductionincervicalcancercells AT yaduvanshishivani taxifolinandlucidinaspotentiale6proteininhibitorsp53functionreestablishmentandapoptosisinductionincervicalcancercells AT silvestresamuel taxifolinandlucidinaspotentiale6proteininhibitorsp53functionreestablishmentandapoptosisinductionincervicalcancercells AT duarteanapaula taxifolinandlucidinaspotentiale6proteininhibitorsp53functionreestablishmentandapoptosisinductionincervicalcancercells AT santosadrianao taxifolinandlucidinaspotentiale6proteininhibitorsp53functionreestablishmentandapoptosisinductionincervicalcancercells AT soareschristianep taxifolinandlucidinaspotentiale6proteininhibitorsp53functionreestablishmentandapoptosisinductionincervicalcancercells AT kumarveerendra taxifolinandlucidinaspotentiale6proteininhibitorsp53functionreestablishmentandapoptosisinductionincervicalcancercells AT passarinhaluis taxifolinandlucidinaspotentiale6proteininhibitorsp53functionreestablishmentandapoptosisinductionincervicalcancercells AT sousaangela taxifolinandlucidinaspotentiale6proteininhibitorsp53functionreestablishmentandapoptosisinductionincervicalcancercells |